Current research suggests that the main adverse effect of caplacizumab is mucocutaneous bleeding, and it may delay the recovery of severe ADAMTS-13 deficiency.[12] This drug is not yet approved in China and was therefore not used in this case. The gene discussed is ADAMTS13; the disease is hyperinsulinemic hypoglycemia, familial, 4.